Search
Ibudilast
go.drugbank.com/drugs/DB05266InvestigationalIbudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume
International brands: Ke TasDidesmethylrocaglamide
go.drugbank.com/drugs/DB15496Experimental[A186802,A186763,A186781,A186784] Of the known derivatives of rocaglamide, didesmethylrocaglamide appears to carry the most potent anti-tumour activity.[A186802,A186805] … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus _Aglaia_.
Aluminum zirconium trichlorohydrex gly
go.drugbank.com/drugs/DB11116ApprovedWithdrawnThe compound forms a colloidal plug in sweat pores, preventing sweat from leaving the body. … Aluminum zirconium trichlorohydrex gly is a common active ingredient in deodorant and antiperspirant products for the over-the-counter use.
Sovateltide
go.drugbank.com/drugs/DB06138InvestigationalIn animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. It is being developed as an adjunct to chemotherapy.
IGN311
go.drugbank.com/drugs/DB04988ExperimentalIGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
go.drugbank.com/drugs/DB01632ApprovedWithdrawnThe key substance in the biosynthesis of histidine, tryptophan, and purine and pyrimidine nucleotides.
Ragweed pollen extract
go.drugbank.com/drugs/DB05368ApprovedWithdrawnThe company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy.
Brasofensine
go.drugbank.com/drugs/DB04857ExperimentalBrasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K. … In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.
Iohexol
go.drugbank.com/drugs/DB01362ApprovedInvestigationalIts low systemic toxicity is the combined result of low chemotoxicity and low osmolality.